Blue Fin Group is proud to announce the promotion of Bruce Phelan to Partner, effective April 1, 2021. Bruce has over 30 years of industry and consulting experience. He is a skilled and trusted advisor to clients, including Chief Commercial Officers and leaders of marketing, market access, field sales, patient services and trade & distribution […]Read Full Article
Welcome to the Blue Fin Group Information Library. Our consultants regularly publish white papers, case studies and articles, lead workshops, deliver speaking engagements, and share opinions on topics of interest to decision makers in the healthcare industry.
You don’t become an industry leader without having alot to say—click on the video vignettes below to hear our expert’s perspectives on a range of topics.
Blue Fin Group is often sought out as an expert commentator by industry publications — featuring our latest thinking and timely insights on the issues that matter most to the healthcare industry.
Blue Fin Group keeps a lens trained on many facets of the healthcare industry, and our white papers focus on singular topics that are relevant and timely. Known for our out-of-the-box thinking, these insights provide a deeper dive or different viewpoint from what others in the industry provide.
Case studies that show the transformation from challenge to solution. Each one details the existing situation, Blue Fin Group’s unique approach, the solution deployed, and the results achieved on behalf of the client. At Blue Fin Group, we deliver Deep Knowledge. Powerful Results.
Deep knowledge, unique insights and powerful perspectives focused on the healthcare industry, provided by Blue Fin Group associates.
What does “innovative” pricing and contracting really mean? It is a topic that has been long debated by Pricing and Market Access professionals and within Managed Markets and is gaining more traction with the increasing cost of therapies. Although we are all working virtually due to the pandemic, our world in Market Access is certainly […]Read Full Article
Specialty Patient Continuity is often blocked by bureaucracy and risk aversion, but progress is now moving at light-speed, creating unimaginable opportunities. Join Kristine Lemke, Senior Principal, who will moderate an expert life sciences specialty panel as they discuss “Specialty Patient Continuity in a New Era of Opportunities” on Thursday, June 11 at 1pm EST. Register here: […]Read Full Article
Juggling the demands of career, marriage and motherhood, I confess that this year I was not very focused on the fact that International Women’s Day was being celebrated on Sunday, March 8. Until an on-line article caught my eye, informing that for the first time ever, an all-female crew would be announcing and producing an […]Read Full Article
International Women’s Day is celebrated on Sunday, March 8, with the theme of “An Equal World is an Enabled World.” As the Human Resources Director at Blue Fin Group, I understand the importance of recognizing and celebrating a day to acknowledge the impact of women in business and leadership. I am proud to work for […]Read Full Article
On Rare Disease Day 2020, we acknowledge the more than 7,000 rare diseases impacting approximately 30 million American patients and roughly 300 million patients worldwide. Rare Disease Day is meant to remind us all that despite the amazing scientific discovery, product approvals and commercialization of new therapies, there remains a high unmet medical need in […]Read Full Article
Blue Fin Group is pleased and proud to announce that Bill Nolan, Principal Consultant, has joined our firm effective February 3, 2020. He brings deep cross-functional experience that will benefit our clients tremendously from the perspective of product strategy, policy and reimbursement, payer strategy and market access, patient access and affordability, provider, pharmacy, distribution and […]Read Full Article
As I prepare to head out to Scottsdale Arizona for the HSCA conference to speak with Health Systems and their GPOs on what the next 3-5 years hold for us, the number one issue facing this class of trade is helping them recognize that the product landscape and reimbursement have shifted on them but they […]Read Full Article